Molecular Pharmacology (USA), Ltd. (MLPH) Stock

About Molecular Pharmacology (USA), Ltd.

As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.

Molecular Pharmacology (USA), Ltd. is headquartered in AU.

Molecular Pharmacology (USA), Ltd. (MLPH) stock trades at $0.02 with a market capitalization of $403819. The stock is valued at a price-to-earnings (P/E) ratio of -336.52, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.49, and currently trades 95.9% below its 52-week high.

On profitability, Molecular Pharmacology (USA), Ltd. generates a return on equity (ROE) of 0.00%, return on capital employed of 0.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: molpharm.aspetjournals.org/